SOTERIA and Tempus team up to offer advanced cancer genomic sequencing for US military members.

SOTERIA Precision Medicine Foundation has partnered with Tempus to provide personalized cancer treatment insights and advanced genomic sequencing to active-duty and veteran military members in the U.S. This collaboration supports SOTERIA's Cancer Hunt initiative, aiming to improve cancer care by using AI-driven genomic profiling to identify targeted therapies and clinical trials. The partnership addresses the rising incidence of cancer at younger ages among military populations by offering precision oncology navigation and comprehensive molecular data to guide treatment. Together, they aim to enhance cancer care pathways and research for military patients.

Tempus AI (TEM) shares surged 10.28% to USD 83.87 on Pluang as of Nov 10, 2026 04:51 WIB, nearing their 52-week high of USD 85.08. The stock's market cap stands at $13.87 billion with a daily volume of over 6.2 million shares. This strong trading activity coincides with the announcement of Tempus's collaboration with SOTERIA to enhance precision oncology for U.S. military and veterans.